Slider Test11.jpg about us Accelerating treatments to help cancer patients achieve durable responses and a better quality of life At Portage Biotech, we are driving the development of first-in-class immuno-oncology therapies and using our diverse drug platforms and strong industry network to identify novel assets and asset combinations. Slide 2 with Overlay Portage Biotech has built a portfolio of five platforms, initially yielding ten novel assets that uniquely target diverse cancer resistance pathways. To learn more, see our full pipeline below. our portfolio Targeting known checkpoint resistance pathways

Who we are

Portage Biotech (NASDAQ: PRTG) is a clinical-stage immuno-oncology company advancing first-in-class therapies that target known checkpoint resistance pathways to achieve durable treatment response and improve quality of life for patients with cancer. We aim to revolutionize cancer research and development and have created a model dedicated to the advancement of diverse drug platforms, bolstered by proven practices from drug discovery veterans and a strong industry network. The result is a viable product development strategy that supports commercial potential and company growth.

Portage actively engages in the drug development process and provides strategic counsel to guide novel immunotherapy assets and asset combinations from bench through human proof of concept. Our team of scientists, clinicians, and pharma-experienced executives have a long history of success, collectively contributing to five oncology drug approvals and creating high-value exits. We reduce the risks associated with early clinical development through more efficient capital management and scientific oversight, and our fail-fast approach enables us to continuously review hundreds of assets and asset combinations, selecting only the most promising to advance. Currently, our portfolio consists of five diverse drug platforms, with 10 products currently in preclinical or clinical development.

News